Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text Free
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Goebl, N.
Right arrow Articles by Brown-Augsburger, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goebl, N.
Right arrow Articles by Brown-Augsburger, P. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Development of a Sensitive and Specific in Situ Hybridization Technique for the Cellular Localization of Antisense Oligodeoxynucleotide Drugs in Tissue Sections

Nancy Goebl1, Brian Berridge2, Victor J. Wroblewski1 and Patricia L. Brown-Augsburger1

1 Eli Lilly & Company, Drug Disposition Development/Commercialization Indianapolis, IN 46285, USA
2 Eli Lilly & Company—Pathology and Toxicology, Indianapolis, IN 46285, USA

Correspondence: Address correspondence to: Nancy Goebl, Eli Lilly & Company—Drug Disposition, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA; e-mail: goebl nancya{at}lilly.com

A sensitive method has been developed for the identification and assessment of phosphorothioate oligonucleotide accumulation in dosed animal tissues using an in situ hybridization approach, which is both sequence specific yet adaptable to every antisense oligonucleotide (ASO), which has been tested to date. Hybridization is accomplished using a digoxigenin-tailed oligonucleotide probe complementary to the ASO target sequence on routinely processed paraffin sections which have been pretreated with a mild target retrieval solution. The DIG-labeled probe is amplified first with an anti-DIG:FITC antibody conjugate followed by an anti:FITC Alexa 488 antibody, then visualized using FITC epifluorescence microscopy. Fluorescent labeling of ASO drug in tissue sections by this method confirms that H&E basophilia previously observed in dosed tissues represents largely intact ASO. However, the fluorescent method enables a wider assessment of tissue distribution in a variety of tissue types due to increased sensitivity and lower signal to noise than can be obtained through an examination of H&E stained tissue sections alone.

Key Words: in situ hybridization • antisense • phosphorothioate • 2-methoxyethyl

Abbreviations: ASO, antisense oligonucleotide • CGE, capillary gel electrophoresis • DIG, digoxigenin • ELISA, enzyme-linked immunosorbent assay • FISH, fluorescence in situ hybridization • FITC, fluorescein isothiocyanate • GCGR, glucagon receptor • KLH, keyhole limpet hemocyanin • PBS, phosphate-buffered saline • SSPE, saline-sodium phosphate-EDTA

Toxicologic Pathology, Vol. 35, No. 4, 541-548 (2007)
DOI: 10.1080/01926230701338958


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?